
Around 100 women a year with advanced breast cancer will be able to try a new type of immunotherapy on the NHS.
The National Institute for Health and Care Excellence (Nice) has overturned its draft rejection of Keytruda (pembrolizumab) and has said women can take the drug in combination with chemotherapy.